Real-world effects of lumacaftor/ivacaftor (LUM/IVA) in people with cystic fibrosis (pwCF): final results of a long-term safety study using US CF Foundation Patient Registry and UK CF Patient Registry data

Source: International Congress 2022 – Advances in cystic fibrosis research

Session: Advances in cystic fibrosis research
Session type: Oral Presentation
Number: 2917

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
C. Kim (Boston, United States), S. Tian (Boston, United States), R. Zahigian (Boston, United States), A. Elbert (Bethesda, United States), S. Charman (London, United Kingdom), S. Carr (London, United Kingdom), D. Nazareth (Liverpool, United Kingdom). Real-world effects of lumacaftor/ivacaftor (LUM/IVA) in people with cystic fibrosis (pwCF): final results of a long-term safety study using US CF Foundation Patient Registry and UK CF Patient Registry data. 2917

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.

Related content which might interest you:

• Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
• Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
• Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living